DOI: http://dx.doi.org/10.18203/2349-3933.ijam20195251

Drug resistance profile among multi-drug resistant tuberculosis patients at diagnosis and correlation with history of anti-tubercular treatment in a tertiary care center

Rahul Kumar, Rajiv Garg, Silpa Kshetrimayum, Amita Jain

Abstract


Background: Drug Resistant Tuberculosis (DR-TB) is a major threat to the realization of the goal of a TB free world in the near future. It is important to study the reasons for the increasing number of such cases so that effective action can be taken to control this growing epidemic.

Methods: Sputum from 36 patients diagnosed with acquired pulmonary Multidrug Resistant Tuberculosis (MDR-TB) were subjected to first- and second-line Drug Sensitivity Testing (DST) after liquid culture in mycobacterium growth Indicator Tube (MGIT). Primary MDR-TB cases were excluded. The relation of the drug sensitivity profile with the history of prior treatment taken was statistically analysed.

Results: Majority of the patients had received appropriate treatment, and most had adhered to prescribed treatment. Among the 36 patients, 24(66.7%) were found to be Pre-Extensively Drug Resistant (Pre-XDR-TB) and 4(11.1%) were extensively drug resistant XDR-TB cases. Inappropriate prescription of fluoroquinolone (FQ) was found to be most common. Prior intake of any drug was not found to significantly affect subsequent resistance to that drug.

Conclusions: Fluoroquinolone resistance is quite common in patients with DR-TB (66.7%). This study did not find the prior use of FQ or any other drug to significantly affect subsequent resistance to the drug. Primary drug resistance is thus a major concern. 11.1% patients were found to be XDR-TB cases. Hence DST for first- and second-line drugs should be done at the time of diagnosis to avoid failure of treatment with a predesigned regimen.


Keywords


Drug resistant tuberculosis, Drug sensitivity testing, Extensively drug resistant, Fluoroquinolone, Multidrug resistant, Multidrug resistant

Full Text:

PDF

References


WHO. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health organization;2019. Licence:CCBY-NC-SA3.OIGO. Available at: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1. Accessed 30 September 2019.

Global tuberculosis report 2018. Geneva: World Health Organization; 2018 WHO/CDS/TB/2018.20. Available at: http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf. Accessed 2 October 2019.

Adwani S, Desai U, Joshi JM. Prevalence of pre extensively drug resistant tuberculosis (Pre XDR TB) and extensively drug resistant tuberculosis (XDR TB) among pulmonary multidrug resistant tuberculosis (MDR TB) at a tertiary care center in Mumbai. JKIMSU. 2016;5:139.

Olusoji D, Eltayeb O, Olanrewaju O, Olapade GD. Pre-extensive Drug resistance tuberculosis (Pre-XDR-TB) among MDR-TB Patients in Nigeria. Global Advan Res J Microbiol. 2013;2(2):022-5.

Singhal P, Dixit P, Singh P, Jaiswal I, Singh M, Jain A. A Study on Pre-XDR and XDR Tuberculosis and Their Prevalent Genotypes in Clinical Isolates of Mycobacterium Tuberculosis in North India. Ind J Med Res. 2016;145:341-7.

Rifat M, Milton AH, Hall J, Oldmeadow C, Islam MA, Husain A, et al. Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors. PLoS One. 2014;9:e105214.

Sharma SK, Turaga KK, Balamurugan A, Saha PK, Pandey RM, Jain NK, et al. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect Genet Evol. 2003 Sep;3(3):183-8.

Ejaz M, Siddiqui AR, Rafiq Y, Malik F, Channa A, et al. Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at-risk groups. Trans R Soc Trop Med Hyg. 2010 Aug; 104(8):511-7.

Songhua C, Pengcheng H, Xiaomeng W, et al. Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case–control study. Int J Infect Dis. 2013;17:e1116-20.

Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. gyrA Mutations and Phenotypic Susceptibility levels to Ofloxacin and Moxifloxacin in Clinical Isolates of Mycobacterium tuberculosis. J Antimicro Chemo. 2012;67:1088-93.

Murray H, Tay EL, Dinh S, Matthews H, Street A, Denholm JT. The Use of Fluoroquinolones for Tuberculosis in Victoria between 2011 and 2016. Tubercul Res Treat. 2018.

van der Heijden YF, Maruri F, Blackman A, et al. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int J Antimicro Agents. 2013;42:232-7.

Migliori GB, Langendam MW, D’ambrosio L, Centis R, Blasi F, Huitric E, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J. 2012;40:812-22.

Shakoor S, Tahseen S, Jabeen K, et al. Fluoroquinolone consumption and -resistance trends in Mycobacterium tuberculosis and other respiratory pathogens: ecological antibiotic pressure and consequences in Pakistan, 2009-2015. Int J Mycobacteriol 2016;5:412-6.

Che Y, Song Q, Yang T, et al. Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use. Eur Respir J 2017;50:1701633.

Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May, et al. Fluoroquinoloneresistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009;180:365-70.

Hamusse SD, Teshome D, Hussen MS, Demissie M, Lindtjørn B. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. BMC Pub Health. 2016;16:593.

Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol. 1993 Jan 1;144(2):104-10.

Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008 Jan 1;46(1):42-9.

Smith SE, Ershova J, Vlasova N, Nikishova E, Tarashova I, Eliseev P, et al. Risk factors for acquisition of drug resistant tuberculosis treatment, Arkhangelsk Oblast, Russia 2005-2010. Emerg Infect Dis. 2015;21:1002-11.

Mannan MAU, Mushtaq A, Naqvi S. Prevalence of Pre-XDR-TB, XDR-TB among MDR-TB Patients Registered at PMDT Site Nishtar Hospital Multan Pakistan. Eur Resp J. 2017;50:PA2764.

Tasnim T, Tarafder S, Alam FM, Sattar H, Kamal SM. Pre-Extensively Drug Resistant Tuberculosis (Pre-XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patients in Bangladesh. J Tubercul Res. 2018;6:199-206.

Porwal C, Kaushik A, Makkar N, Banavaliker JN, Hanif M, Singla R, et al. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One. 2013;8:e55299.

Ignatyeva O, Balabanova Y, Nikolayevskyy V, Koshkarova E, Radiulyte B, Davidaviciene E, et al. Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries. Tuberculosis. 2015;95:581-8.

World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva: WHO; 2014. Available at: https://www.who.int/tb/publications/pmdt_companionhandbook/en/